bioAffinity Technologies (NASDAQ:BIAF) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of bioAffinity Technologies (NASDAQ:BIAF) from a hold rating to a sell rating in a report released on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday, July 20th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, bioAffinity Technologies has a consensus rating of “Sell”.

bioAffinity Technologies Price Performance

Shares of NASDAQ:BIAF opened at $0.63 on Friday. The company has a market cap of $2.97 million, a price-to-earnings ratio of -0.05 and a beta of -1.04. The firm’s 50-day simple moving average is $1.04 and its 200-day simple moving average is $1.67. The company has a quick ratio of 1.34, a current ratio of 1.36 and a debt-to-equity ratio of 0.15. bioAffinity Technologies has a fifty-two week low of $0.56 and a fifty-two week high of $13.50.

bioAffinity Technologies (NASDAQ:BIAF) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.40) by $1.59. bioAffinity Technologies had a negative net margin of 280.53% and a negative return on equity of 285.75%. The business had revenue of $1.35 million for the quarter, compared to analyst estimates of $1.48 million.

Institutional Investors Weigh In On bioAffinity Technologies

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC purchased a new position in bioAffinity Technologies in the 4th quarter valued at approximately $36,000. Scientech Research LLC purchased a new stake in bioAffinity Technologies during the third quarter worth $49,000. Finally, J. Safra Sarasin Holding AG purchased a new stake in bioAffinity Technologies during the first quarter worth $164,000. Hedge funds and other institutional investors own 1.64% of the company’s stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.